DaVita (NYSE:DVA) Issues Earnings Results, Beats Estimates By $0.10 EPS

DaVita (NYSE:DVA - Get Free Report) posted its quarterly earnings data on Thursday. The company reported $2.24 EPS for the quarter, beating analysts' consensus estimates of $2.14 by $0.10, Zacks reports. DaVita had a return on equity of 88.18% and a net margin of 6.53%. DaVita updated its FY 2025 guidance to 10.200-11.300 EPS.

DaVita Stock Performance

NYSE:DVA traded down $20.11 during mid-day trading on Monday, hitting $156.95. 5,110,690 shares of the company traded hands, compared to its average volume of 534,172. The stock's fifty day moving average price is $161.39 and its 200-day moving average price is $157.80. DaVita has a one year low of $118.56 and a one year high of $179.60. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The firm has a market cap of $12.87 billion, a price-to-earnings ratio of 16.93, a price-to-earnings-growth ratio of 0.84 and a beta of 0.94.

Wall Street Analysts Forecast Growth

Separately, Barclays upped their price objective on DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.